December 8, 2017 06:44 AM ESTUpdated 06:57 AM

Denali IPO hits a 2017 record $1.7B market valuation, raising $250M for neurodegeneration R&D

John Carroll

Editor & Founder

Denali Therapeutics’ team plans to break through a lot of barriers in biotech — most notably looking to develop a drug for Alzheimer’s that actually works …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Denali IPO hits a 2017 record $1.7B market valuation, raising $250M for neurodegeneration R&D

John Carroll

Editor & Founder

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

De­nali IPO hits a 2017 record $1.7B mar­ket val­u­a­tion, rais­ing $250M for neu­rode­gen­er­a­tion R&D

John Carroll

Editor & Founder

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Denali IPO hits a 2017 record $1.7B market valuation, raising $250M for neurodegeneration R&D

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?